San Diego, CA 1/3/18—Maravai LifeSciences, a provider of specialty reagents to researchers, biotherapeutics manufacturers and OEM partners, has acquired Glen Research for an undisclosed amount. Virginia-based Glen Research offers reagents for DNA and RNA synthesis. “The acquisition supports our commitment to the genomics market, which we first entered with the acquisition of TriLink BioTechnologies last year. Glen Research’s commitment to quality and customer service fits perfectly with the Maravai brand,” commented Maravai LifeSciences President Eric Tardif.

In 2016, Maravai LifeSciences acquired three companies: Vector Laboratories, which provides labeling and detection reagents (see IBO 5/15/16); TriLink Biotechnologies, which produces nucleic acids; and Cygnus Technologies, which supplies specialized reagents for the process development and QC of biologics.

Including this purchase, Maravai LifeSciences currently has 222 employees and greater than $100 million in trailing 12-month revenue­s, according to Vice President and CCO David Weber. Describing the company’s goals, he told IBO, “Maravai LifeSciences catalyzes the growth of successful pioneering life science companies by providing the expertise, capital, processes and systems so that they can continue to serve scientists to improve human health.”

Mr. Weber added, “Our stated goal is to build a growing, profitable and transformative life sciences research products company. Our current focus markets are genomics, biotherapeutics and tissue pathology, and we are a market leader in areas such as oligonucleotide synthesis and chemistry, biopharmaceutical impurity analysis and immunohistochemistry.”